玻璃体内注射阿柏西普治疗糖尿病黄斑水肿的疗效

Intravitreal injection of Aflibercept for the treatment of diabetic macular edema

目的:研究玻璃体内注射阿柏西普(IVA)治疗糖尿病黄斑水肿(DME)的治疗效果。方法:对2018年7月至2019年1月在武汉大学人民医院眼科行IVA治疗的DME患者32例(44眼)的临床资料进行回顾性分析,比较行阿柏西普玻璃体内注射4周后最佳矫正视力(BCVA)及黄斑中心凹厚度(CMT)变化。结果:IVA治疗后4周,41只眼视力较术前提高(93. 2%),3只眼视力无改善(6. 8%),总体患眼BCVA与治疗前相比差异具有统计学意义(t=14. 946,P<0. 01);且注射后黄斑区水肿减轻,CMT较术前明显降低,差异具有统计学意义(t=27. 497,P<0. 01)。结论:玻璃体内单次注射阿柏西普治疗DME在视力提高及黄斑水肿改善方面均有较好的效果。

Objective:To study the efficacy of intravitreal injection of Aflibercept(IVA)for the treatment of diabetic macular edema(DME).Methods:Clinical data of 32 DME patients(44 eyes)treated with IVA from July 2018 to January 2019 in Renmin Hospital of Wuhan University were analyzed retrospectively.The best corrected visual acuity(BCVA)and central macular thickness(CMT)were compared after intravitreal injection of Aflibercept for four weeks.Results:Four weeks after IVA,the visual acuity of 41 eyes was improved(93.2%),and the difference was significant between before and after injection(t=14.946,P<0.01);Macular edema was alleviated after injection and CMT was significantly lower than that before injection,and the differences were statistically significant(t=27.497,P<0.01).Conclusion:Single intravitreal injection of Aflibercept in the treatment of DME has good effect on improving visual acuity and macular edema.